Age-related changes in protein binding of drugs. Implications for therapy

Clinical Pharmacokinetics

Volumn 38, Issue 3, 2000, Pages 271-290

  Grandison, Monica K ^a   Boudinot, F Douglas ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETAZOLAMIDE; ALBUMIN; ALFENTANIL; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BATANOPRIDE; BENAZEPRIL; CAFFEINE; CANRENONE; CEFONICID; CEFTRIAXONE; CHLORDIAZEPOXIDE; CHLOROQUINE; CHLORPROMAZINE; CLADRIBINE; CLOMETHIAZOLE; DESIPRAMINE; DIAZEPAM; DIFLUNISAL; DIGITOXIN; DIURETIC AGENT; DONEPEZIL; DRUG; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMA PROTEIN; UNINDEXED DRUG;

AGING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW;

EID: 0034117268     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038030-00005     Document Type: Review

References (162)

1. 1. Greenblatt DJ, Sellers EM, Koch-Weser J. Importante of protein binding for the interpretation of serum of plasma drug concentrations. J Clin Pharmacol 1982 May-Jun; 22 (5-6): 259-63
2. 2. Ariëns EJ. Drug levels in the target tissue and effect Clin Pharmacol Ther 1974 Jul; 16 (1): 155-75
3. 3. Oosterhuis B, van Boxtel CJ. Kinetics of drug effects in man. Ther Drug Monit 1988; 10 (2): 121-32
4. 4. Wright JD, Boudinot FD. Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996 Jun; 30 (6): 445-62
5. 5. Blum MR, Riegelman S, Becker CE. Altered protein binding of diphenylhydantoin in uremic plasma [letter]. N Engl J Med 1972 Jan; 286 (2): 109
6. 6. Odar-Cederlof I, Lunde P. Sjogvist F. Abnormal pharmacokinetics of phenytoin in a patient with uremia. Lancet 1970 Oct; 11 (7677): 831-2
7. 7. Gibaldi M, Koup JR. Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol 1981; 20 (4): 299-305
8. 8. Kunin CM, Craig WA, Kornguth M, et al. Influence of protein binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973 Nov; 226: 214-24
9. 9. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980 May-Jun; 5 (3): 246-62
10. 10. Kishino S, Nomura A, Di ZS, et al. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency. Ther Drug Monit 1995 Oct; 17 (5): 449-53
11. 11. Kremer JMH, Wilting J, Janssen LHM. Drug binding of human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988 March; 40 (1): 1-47
12. 12. Caswell M, Pike LA, Bull BS, et al. Effect of patient age on tests of acute-phase response. Arch Pathol Lab Med 1993 Sep; 117 (9): 906-10
13. 13. Crook MA, Treloar A, Haq M, et al. Serum total sialic acid and other acute phase proteins in elderly subjects. Eur J Clin Chem Clin Biochem 1994 Oct; 32 (10): 745-7
14. 14. Lalonde RL, Tenero DM, Burlew BS, et al. Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin Pharmacol Ther 1990 Apr; 47 (4): 447-55
15. 15. Veering BT, Burm AG, Souverijn JH, et al. The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 1990 Feb; 29 (2): 201-6
16. 16. Ecoffey C. Pharmacokinetics of local anesthetics in children. Cah Anesthesiol 1992; 40 (7): 533-6
17. 17. Seta N, Tissot B, Forestier F, et al. Changes in alpha 1-acid glycoprotein serum concentrations and glycoforms in the developing human fetus. Clin Chim Acta 1991 Dec; 203 (2-3): 167-75
18. 18. Bardy AH, Hiilesmaa VK, Teramo K, et al. Protein binding of antiepileptic drugs during pregnancy, labor and puerperium. Ther Drug Monit 1990 Jan; 12 (1): 40-6
19. 19. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990 Jan; 18 (1): 20-36
20. 20. Maher JE, Goldenberg RL, Tamura T, et al. Albumin levels in pregnancy: a hypothesis - decreased levels of albumin are related to increased levels of alpha-fetoprotein. Early Hum Dev 1993 Oct; 34 (3): 209-15
21. 21. Meistelman C, Benhamou D, Barre J, et al. Effects of age on plasma protein binding of sufentanil. Anesthesiology 1990 Mar; 72 (3): 470-3
22. 22. Jensen H, Rossing N, Andersen SB, et al. Albumin metabolism in the nephrotic syndrome in adults. Clin Sci 1967 Dec; 33 (3): 445-57
23. 23. Vasson MP, Baguet JC, Arveiller MR, et al. Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron 1993; 65 (2): 299-303
24. 24. Movin-Osswald G, Boelaert J, Hammarlund-Udenaes M, et al. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol 1993 Jun; 35 (6): 615-22
25. 25. Vasson MP, Paul JL, Coudere R, et al. Serum alpha-1 acid glycoprotein in chronic renal failure and hemodialysis. Int J Artif Organs 1991 Feb; 14 (2): 92-6
26. 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 1986; 8 (3): 259-63
27. 27. Garcia-Morillas M, Gil-Extremera B, Caracuel-Ruiz. Differential effects of hepatic cirrhosis on the plasma protein binding of drugs. Int J Clin Pharmacol Res 1984; 4 (5): 327-33
28. 28. Hallen J, Laurell CB. Plasma protein pattern in cirrhosis of the liver. Scand J Clin Lab Invest Suppl 1972; 124: 97-103
29. 29. Kindmark CO, Laurell CB. Sequential changes of the plasma protein pattern in inoculation hepatitis. Scand J Clin Lab Invest Suppl 1972; 124: 105-15
30. 30. Joelsson B, Alwmark A, Gullstrand P, et al. Serum proteins in liver cirrhosis: effects of shunt surgery. J Clin Chem Clin Biochem 1987 Dec; 25 (12): 865-8
31. 1-acid glycoprotein in two benign liver diseases: alcoholic cirrhosis and acute hepatitis. Clin Chim Acta Dec 1989; 186 (1): 59-66
32. 32. Falleti E, Pirisi M, Fabris C, et al. Increase of serum alpha 1-acid glycoprotein despite the decline of liver synthetic function in cirrhotics with hepatocellular carcinoma. Eur J Clin Chem Clin Biochem 1993 Jul; 31 (7): 407-11
33. 33. Viani A, Rizzo G, Carrai M, et al. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs. Int J Clin Pharmacol Ther Toxicol 1992 Apr; 30 (4): 128-33
34. 1-acid glycoprotein. N Engl J Med 1978 Dec; 299 (26): 1435-9
35. 35. Bloedow DC, Hansrough JF, Hardin T, et al. Postburn serum drug binding and serum concentrations. J Clin Pharmacol 1986 Feb; 26 (2): 147-51
36. 36. Martyn JAJ, Abernethy DR, Greenblatt DJ. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 1984 Apr; 35 (4): 535-9
37. 37. Tozer TN. Implication of altered plasma protein binding in disease states. In: Benet LZ, Massourd N, Garbetoglio JG, et al., editors. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984
38. 38. Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal, and hepatic disease. Clin Pharmacol Ther 1974 Mar; 15: 276-82
39. 39. Wallace S, Brodie MJ. Decreased drug binding in serum from patients with chronic hepatic disease. Eur J Clin Pharmacol 1976 Mar; 9 (5-6): 429-32
40. 40. Riuz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984; 36: 691-5
41. 41. Grossman SH, Davis D, Kitchell BB, et al. Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 1982 Mar; 31 (3): 350-7
42. 42. Thiessen JJ, Sellers EM, Denbeigh P, et al. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol 1976 Jul; 16 (7): 345-51
43. 43. Feely J, Stevenson IH, Crooks J. Altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet 1981 Jul-Aug; 6 (4): 298-305
44. 44. Kurz H, Trunk H, Wetrz B. Evaluation of methods to determine protein binding of drugs. Arzneimittel Forschung 1977 Jul; 27 (7): 1373-80
45. 45. Chigell CU. Protein binding. In: Garnett Er, Hirtz. JL, editors. Drug fate and metabolism. Vol 1. New York: Marcel Dekker, 1977: 187-228
46. 46. Bowers WF, Fulton S, Thompson J. Ultrafiltration vs. equilibrium dialysis for determination of free fraction. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 49-60
47. 47. Pacifici GM, Viana A. Methods of determining plasma and tissue binding of drugs: pharmacokinetic consequences. Clin Pharmacokinet 1992 Dec; 23 (6): 449-68
48. 48. Muller M, Scmid R, Georgopoulos A, et al. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995 Apr; 57 (4): 371-80
49. 49. Schentag JJ, Ballow CH. Tissue directed pharmacokinetics. Am J Med 1991 Sep 12; 91 (3A): 5-11
50. 50. Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1977 Jul-Aug; 2 (4): 252-68
51. 51. Vallner JJ. Binding of drugs by albumin and plasma protein. J Pharm Sci 1977 Apr; 66 (4): 447-63
52. 52. Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 1976; 5 (1): 43-140
53. 53. Sanderberg AA, Slaunwhite WR, Antoniades HN. The binding of steroids and steroid conjugates to human plasma proteins. Recent Progr Horm Res 1957; 13: 209-67
54. 54. Ballard PL. Delivery and transport of glucocorticoids to target cells. Monogr Endocrinol 1979; 12: 25-48
55. 55. Lemaire M, Urien S, Albengres((intials?)), et al. Lipoprotein binding of drugs. In: Reidenberg MM, Erill S, editors. Drug-protein binding. New York: Praeger Publishers, 1986: 36-45
56. 56. MacKichan J. Influence of protein binding and use of unbound (free) drug concentrations (chapter 5). In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokene (WA): Applied Therapeutics, Inc, 1993: 1-48
57. 57. Pike E, Skuterud B, Kierulf P, et al. The relative importance of albumin, lipoproteins and orosomucoid for drug serum binding. Clin Pharmacokinet 1984; 9 Suppl. 1: 84-101
58. 58. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 1981 Mar; 33 (1): 17-53
59. 59. Klotz IM, Physicochemical aspects of drug-protein interactions: a general perspective. Ann N Y Acad Sci 1973 Nov 26; 226: 18-35
60. 60. Peters T. Serum albumin. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 133-87
61. 61. Iwatsuru M, Nishigori H, Maruyama K. The classification of drugs on the basis of the drug-binding site on human serum albumin. Chem Pharm Bull 1982 Dec; 30 (2): 4489-93
62. 62. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975 Nov; 11 (6): 824-32
63. 63. Schmid K. α-1-acid glycoprotein. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 183-228
64. 64. Scanu AM, Edelstein C, Keim P. Serum lipoproteins. In: Putnam FW, editor. The plasma proteins: structure, function and genetic control. New York: Academic Press, 1975: 317-91
65. 65. Pucino F, Beck CL, Seifert RL, et al. Pharmacogeriatics. Pharmacotherapy 1985 Nov-Dec; 5 (6): 314-26
66. 66. Cohen JL. Pharmacokinetic changes in aging. Am J Med 1986 May 16; 80 (5A Suppl.): 31-8
67. 67. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1989 Oct; 17 (4): 236-63
68. 68. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979 Jan; 27 (1): 20-2
69. 69. Leslie C, Scott PJW, Caird FI. Principles of alterations to drug kinetics and dynamics in the elderly. Med Lab Sci 1992 Dec; 49 (4): 319-25
70. 70. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 10-7
71. 71. Smallwood RH, Mihaly GW, Smallwood RA, et al. Effect of a protein change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction. J Pharmacokinet Biopharm 1988 Oct; 16 (5): 529-42
72. 72. Huang J, Øie S. Hepatic elimination of drugs with concentration-dependent serum protein binding. J Pharmacokinet Biopharm 1984 Feb; 12 (1): 67-81
73. 73. Faed EM. Protein binding of drugs in plasma, interstital fluid and tissues: effect on pharmacokinetics. Eur J Clin Pharmacol 1981; 21 (1): 77-81
74. 74. McNamara PJ, Levy G, Gibaldi M. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. J Pharmacokinet Biopharm 1979; 7 (2): 195-206
75. 75. Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983; 14 (3): 427-65
76. 76. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clinical pharmacokinetics in the elderly. Clin Pharmacokinet 1987 Jan; 12 (1): 41-7
77. 77. Wagner JG, Northam JI, Alway CD, et al. Blood levels at the equilibrium state after multiple dosing. Nature 1965 Sep 18; 207 (3): 1301-2
78. 78. Kutt H, Winters W, Kokenga R. et al. Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 1964; 11: 642-8
79. 79. Piquette-Miller M, Foster RT, Kappagoda CT, et al. Effect of aging on the pharmacokinetics of acebutolol enantiomers. J Clin Pharmacol 1992 Feb; 32 (2): 148-56
80. 80. Chapron DJ, Sweeney KR, Feig PU, et al. Influence of advanced age on the disposition of acetazolamide. Br J Clin Pharmacol 1985 Mar; 19 (3): 363-71
81. 81. Gomolin IH, Chapron DJ. Elucidating the relationship between acetazolamide plasma protein binding and renal clearance us ing an albumin infusion. J Clin Pharmacol 1992 Nov; 32 (11): 1028-32
82. 82. Lemmens HJM, Burn AGL, Bouill JG, et al. Pharmacodynam ics of alfentanil: the role of plasma protein binding. Anesthesiology 1992 Jan; 76 (1): 65-70
83. 1 acid glycoprotein, albumin and serum, Int J Clin Pharmacol Ther Tox 1991 Mar; 29 (3): 96-102
84. 84. Greenblatt DJ, Divoll M, Abernethy DR, et al. Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch Gen Psychiatry 1983 Mar; 40 (3): 287-90
85. 85. Schulz P, Turner-Tamiyasu K, Smith G, et al. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 1983 Mar; 33 (3): 360-6
86. 86. St Peter JV, Brady ME, Foote EF, et al. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment. Eur J Clin Pharmacol 1993; 45 (1): 59-63
87. 87. Kaiser G, Ackermann R, Durnin CJ, et al. Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol 1990; 38 (4): 379-85
88. 88. MacDonald NJ, Sioufi A. Howie CA, et al. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol 1993 Sep; 36 (3): 205-9
89. 89. Ho PC, Bourne DWA, Triggs EJ, et al. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone. Eur J Clin Pharmacol 1984; 27: 435-9
90. 90. Blanchard J. Protein binding of caffeine in young and elderly males. J Pharm Sci 1982 Dec; 71 (12): 1415-8
91. 91. Karki SD, Bentley DW, Luzier A, et al. Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc 1993 Aug; 41 (8): 808-10
92. 92. Dudley MN, Shyu WC, Nightingale CH. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans. Antimicrob Agents Chemother 1986 Oct; 30 (4): 565-9
93. 93. Luderer JR, Patel IH, Durkin J, et al. Age and ceftriaxone kinetics. Clin Pharmacol Ther 1984 Jan; 35 (1): 19-25
94. 94. Roberts RK, Wilkerson GR, Branch RA, et al. Effect of age and parenchymal liver disease on the disposition and elimination of chlorodiazepoxide. Gastroenterology 1978 Sep; 75 (3): 479-85
95. 95. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27 (1): 91-7
96. 96. Walker O. Birkett DJ, Alvan G, et al. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol 1983 Mar; 15 (3): 375-7
97. 97. Augustijns P, Verbeerke N. Stereoselective pharmacokinetic properties of chloroquine and de-ethyl chloroquine in humans. Clin Pharmacokinet 1993 Mar; 24 (3): 259-69
98. 98. Albertioni F, Heronren L. Protein binding of 2-chloro-2′-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia. Eur J Clin Pharmacol 1994; 46 (6): 563-4
99. 99. Nation RL. Vine J, Triggs EJ, et al. Plasma levels of chlormethiazole and two metabolites after oral administration to young and aged subjects. Eur J Clin Pharmacol 1977 Oct 14; 12 (2): 137-45
100. 100. Abernathy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985 Jan; 232 (1): 183-8
101. 101 Allen MD, Greenblatt DJ. Comparative protein binding of diazepam and desmethydiazepam. J Clin Pharmacol 1981 May-Jun; 21 (5-6): 219-23
102. 102. Shader RI, Greenblatt DJ, Cirraulo DA, et al. Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology 1981; 75 (2): 193-7
103. 103. Viani A, Rizzo G, Carrai M, et al. The effect of aging on plasma albumin and plasma protein binding of diazepam, salicyclic acid, and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 1992 Mar; 33 (3): 299-304
104. 104. Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 302-12
105. 105. Verbeeck RK, De Schepper PJ. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther 1980; 27: 628-35
106. 106. Bonde J. Pedersen LE, Bodtker S, et al. The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol 1985 Nov; 20 (5): 453-8
107. 107. Ohnishi A, Mihara M, Kamakura H, et al. Comparsion of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993 Nov; 33 (11): 1086-91
108. 108. Scatina J, Hicks D. Kraml M, et al. Etodalac kinetics in the elderly. Clin Pharmacol Ther 1986 May; 39 (5): 550-3
109. 109. Carlos R, Calvo R, Erill S. Plasma protein binding of etomidate in different age groups and in patients with chronic respiratory insufficiency. Int J Clin Pharmacol TherToxicol 1981 Apr; 19 (4): 171-4
110. 110. Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981 Oct; 30 (4): 475-86
111. 111. Andreasen F, Hansen U, Husted SE, et al. The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 1983 Oct; 16 (4): 391-7
112. 112. Rowell FJ, Hui SM, Fairburn AF, et al. Total and free serum haloperidol levels in schizophrenic patients and the effect of age, thioridazine and fatty acids on haloperidol serum protein binding in vitro. Br J Clin Pharmacol 1981 Apr: 11 (4): 377-82
113. 113. Rudy AC, Knight PM, Brater DC, et al. Enantioselective disposition of ibuprofen on elderly persons with and without renal impairment. J Pharmacol ExpTher 1995 Apr; 273 (1): 88-93
114. 114. Cusack B, O'Malley K, Lavan J, et al. Protein binding and disposition of lignocaine in the elderly. Eur J Clin Pharmacol 1985; 29 (3): 323-9
115. 115. Divoll M, Greenblatt DJ. Effect of age and sex on lorazepam protein binding. J Pharm Pharmacol 1982 Feb; 34 (2): 122-3
116. 116. Norbury HM, Franklin RA, Graham DF. Pharmacokinetics of the new analgesic, meptazinol after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 1983; 25 (1): 77-80
117. 117. Norbury HM, Franklin RA, Graham DF, et al. Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients. Eur J Clin Pharmacol 1984; 27: 223-6
118. 118. Edno L, Bressolle F, Gomeni R, et al. Total and free metholrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 1996; 18: 128-34
119. 119. Rigby JW, Scott AK, Hawksworth GM, et al. A comparsion of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young subjects. Br J Clin Pharmacol 1985 Oct; 20 (4): 327-31
120. 120. Greenblatt DJ, Abernathy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984 Jul; 61 (1): 27-45
121. 121. Cook CS, Schoenhard GL, Karim A. Effect of salicylic acid on the plasma protein binding and the misoprostol acid. J Pharm Sci 1994 Jun; 83 (6): 883-6
122. 122. Upton RA, Williams RL, Kelly J, et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984; 18: 207-14
123. 123. Sugioka N, Koyama H, Kawakubo M, et al. Age-dependent alteration of the serum-unbound fraction of nicardipine, a calcium-channel blocker, in man. J Pharm Pharmacol 1996 Dec; 48 (12): 1327-31
124. 124. Jochemsen R, Van Beusekom Br. Spoelstra P, et al. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol 1983 Mar; 15 (3): 295-302
125. 125. Greenblatt DJ, Abernathy DR, Locniskar A, et al. Age, sex and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther 1985 Dec; 38 (6): 697-703
126. 126. Greenblatt DJ, Matlis R, Scavone JM, et al. Oxaprozin kinetics in the elderly. Br J Clin Pharmacol 1985 Jan; 19 (1): 373-8
127. 127. Karim A, Noveck R, McMahon G, et al. Oxaprozin and piroxicam, nonsteriodal anti-inflammatory drugs with long half-lives: effect of protein binding differences on steady state pharmacokinetics. J Clin Pharmacol 1997 Apr; 37 (4): 267-78
128. 128. Mather LE, Tucker GT, Pflug AE, et al. Meperidine kinetics in man: intravenous injection in surgical patients and volunteers Clin Pharmacol Ther 1975 Jan; 17 (1): 21-30
129. 129. Holmberg L, Odar-Cederlöft I, Nilsson JLG, et al. Pethidine binding to blood cells and plasma proteins in old and young subjects. Eur J Clin Pharmacol 1982; 22 (2): 457-61
130. 130. Bender AD, Post A, Meier JP, et al. Plasma protein binding of drugs as a function of age. J Pharm Sci 1975 Oct; 64 (10): 1711-3
131. 131. Patterson M, Heazelwood R, Smithhurst B, et al. Plasma protein binding of phenytoin in the aged: in vivo studies. Br J Clin Pharmacol 1982 Mar; 13 (3): 423-5
132. 132. Richardson CJ, Blocka KLN, Ross SG, et al. Effect of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985 Jan; 37 (1): 13-8
133. 133. Trovik TS, Jaeger R, Jorde R, et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992; 43 (3): 265-8
134. 134. Andros E, Detmar-Hanna D, Suteparuk S, et al. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol 1996; 50: 41-6
135. 135. Tenero DM, Bottorff MB, Burlew BS. Altered beta-adrenergic sensitivity and protein binding to l-propranolol in the elderly. J Cardiovasc Pharmacol 1990 Nov; 16 (5) 702-7
136. 136. Gilmore DA, Gal J, Gerber JG, et al. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992 Jun; 261 (3): 1181-6
137. 137. Bendayan R, Pieper JA, Stewart RB, et al. Influence of age on serum protein binding of propranolol. Eur J Clin Pharmacol 1984; 26 (2): 251-4
138. 138. Colagelo P, Chandler M, Bloiun R, et al. Stereoselective binding of propranolol in the elderly. Br J Clin Pharmacol 1989; 27: 519-22
139. 139. Barber HE, Hawksworth GM, Petrie JC, et al. Pharmacokinetics of atenolol and propranolol in young and elderly subjects [abstract]. Br J Clin Pharmacol 1981; 11: 118P-9P
140. 140. Ochs HR, Greenblatt DJ, Woo E, et al. Reduced quinidine clearance in elderly persons. Am J Cardiol 1978 Sep; 42 (3): 481-5
141. 141. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223-9
142. 142. Roberts MS, Rumble RH, Wanwimolruk S, et al. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 1983; 25 (2): 253-61
143. 143. Lesko LJ, Narang PK, Yeager L, et al. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration. Eur J Clin Pharmacol 1985; 28 (3): 339-45
144. 144. Carr RA, Pasutto FM, Lewanczuk RZ, et al. Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration. Biopharm Drug Dispos 1995 Nov; 16 (8): 705-12
145. 145. Varoquaux O, LaJoie D, Gobart C, et al. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly. Br J Clin Pharmacol 1985 Dec; 20 (6): 575-81
146. 146. Caldwell JR, Kirby DS, Gardner MJ, et al. The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Br J Clin Pharmacol 1995; 39 (I Suppl): 3S-9S
147. 147. Shin SG, Juan D, Rammohan M. Theophylline pharmacokinetics in normal elderly subjects. Clin Pharmacol Ther 1988 Nov; 44 (5): 522-30
148. 148. Antal EJ, Kramer PA, Mercik SA, et al. Theophylline pharmacokinetics in advanced age. Br J Clin Pharmcol 1981; 12 (5) 637-45
149. 149. Lesko LJ, Tabor KJ, Johnson BF. Theophylline serum protein binding in obstructive airways disease. Clin Pharmacol Ther 1981 Jun; 29 (6): 776-81
150. 150. Nilsen OG, Storhaug A, Dale O. Binding of tiaprofenic acid to human sera and isolated serum proteins. Arzneimettel Forschung 1985; 35 (6); 984-7
151. 151. Greenblatt DJ, Divoll M, Abernathy DR, et al. Reduced clearance of triazolam in old age: relationot antipyrine oxidizing capacity. Br J Clin Pharmacol 1983 Mar; 15 (3): 303-9
152. 152. Perucca E, Grimaldi R, Gotti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984 Jun; 17 (6): 665-9
153. 153. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985 Jun; 37 (6): 697-700
154. 154. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984; 36: 803-9
155. 155. Wood DM, Ford JM, Roberts CJC. Variability in the plasma protein binding of velnacrine: a potential agent for Alzheimer's disease. Eur J Clin Pharmacol 1996; 50: 115-9
156. 156. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 509-17
157. 157. Shepherd AMM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977 Jun; 4 (3): 315-20
158. 158. Braeckman RA, Granneman GR, Locke CS, et al. The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet 1995; 29: 42-8
159. 159. Van Den Ouweland FA, Jansen PAF, Tan Y, et al. Pharmacokinetics of high-dosage naproxen in elderly patients. Int J Clin Pharmacol Ther Toxicol 1988; 26 (3): 143-7
160. 160. Hundal Ø, Rugstad HE, Husby G. Naproxen free plasma concentrations and unbound fractions in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Ther Drug Monit 1991; 13: 478-84
161. 161. Satterwhite JH, Boudinot FD. Age-and dose-dependent naproxen disposition in Fischer 334 rats. J Gerontol 1991; 46 (6): B222-7
162. 162. Satterwhite JH, Boudinot FD. Effects of age on the pharmacodynamics of naproxen in the rat. Exp Gerontol 1995; 30 (5): 505-15